Martin R Weihrauch

Summary

Affiliation: University of Cologne
Country: Germany

Publications

  1. ncbi request reprint [Factitious disorders. Hematologic, neurologic and dermatologic symptoms in a physician with factitious disorder]
    M R Weihrauch
    Klinik I fur Innere Medizin, Universitat zu Koln
    Med Klin (Munich) 96:555-60. 2001
  2. doi request reprint Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment
    Martin R Weihrauch
    Department of Hematology and Oncology, University of Cologne, Germany
    Onkologie 31:464-7. 2008
  3. pmc T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals
    Martin R Weihrauch
    Molecular Tumor Biology and Tumor Immunology, University of Cologne, Köln 50924, Germany
    World J Gastroenterol 14:2529-33. 2008
  4. ncbi request reprint Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer
    Martin R Weihrauch
    Center for Experimental Medicine, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Cancer Res 11:5993-6001. 2005
  5. ncbi request reprint Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor
    Martin R Weihrauch
    Molecular Tumor Biology and Tumor Immunology, University of Cologne, Cologne, Germany
    Cancer Res 65:5516-9. 2005
  6. ncbi request reprint Artificial sweeteners--do they bear a carcinogenic risk?
    M R Weihrauch
    Department of Internal Medicine I of the University of Cologne, Cologne, Germany
    Ann Oncol 15:1460-5. 2004
  7. ncbi request reprint Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia
    Martin R Weihrauch
    Department of Internal Medicine I, University of Cologne, Germany
    Leuk Lymphoma 45:699-704. 2004
  8. ncbi request reprint Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography in lymphoma
    Martin R Weihrauch
    Department of Internal Medicine I, University of Cologne, Cologne, Germany
    Leuk Lymphoma 44:15-22. 2003
  9. ncbi request reprint [Artificial sweeteners--are they potentially carcinogenic?]
    M R Weihrauch
    Klinik I fur Innere Medizin, Universitat zu Koln
    Med Klin (Munich) 96:670-5. 2001
  10. ncbi request reprint Immunomagnetic enrichment and detection of isolated tumor cells in bone marrow of patients with epithelial malignancies
    Martin R Weihrauch
    Department of Internal Medicine I of the University of Cologne, Germany
    Clin Exp Metastasis 19:617-21. 2002

Detail Information

Publications19

  1. ncbi request reprint [Factitious disorders. Hematologic, neurologic and dermatologic symptoms in a physician with factitious disorder]
    M R Weihrauch
    Klinik I fur Innere Medizin, Universitat zu Koln
    Med Klin (Munich) 96:555-60. 2001
    ..The self-reported history was inconsistent and incoherent. On physical examination neurological and dermatological disorders could be found...
  2. doi request reprint Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment
    Martin R Weihrauch
    Department of Hematology and Oncology, University of Cologne, Germany
    Onkologie 31:464-7. 2008
    ..Even with primarily irresectable disease, cure can be achieved in patients who become operable after neoadjuvant treatment. To improve the prognosis of these patients, highly effective neoadjuvant regimens need to be developed...
  3. pmc T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals
    Martin R Weihrauch
    Molecular Tumor Biology and Tumor Immunology, University of Cologne, Köln 50924, Germany
    World J Gastroenterol 14:2529-33. 2008
    ..To evaluate, whether humoral hepatitis-B-vaccine non-responders also fail to mount a T cell response and to compare these results to normal vaccinees...
  4. ncbi request reprint Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer
    Martin R Weihrauch
    Center for Experimental Medicine, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Cancer Res 11:5993-6001. 2005
    ....
  5. ncbi request reprint Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor
    Martin R Weihrauch
    Molecular Tumor Biology and Tumor Immunology, University of Cologne, Cologne, Germany
    Cancer Res 65:5516-9. 2005
    ....
  6. ncbi request reprint Artificial sweeteners--do they bear a carcinogenic risk?
    M R Weihrauch
    Department of Internal Medicine I of the University of Cologne, Cologne, Germany
    Ann Oncol 15:1460-5. 2004
    ..However, according to the current literature, the possible risk of artificial sweeteners to induce cancer seems to be negligible...
  7. ncbi request reprint Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia
    Martin R Weihrauch
    Department of Internal Medicine I, University of Cologne, Germany
    Leuk Lymphoma 45:699-704. 2004
    ..TA is a feasible and efficacious chemotherapeutic combination for the treatment of MDS RAEB, RAEB-t, CMML and AML. For patients of 60 years and older, this regimen is also a safe option...
  8. ncbi request reprint Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography in lymphoma
    Martin R Weihrauch
    Department of Internal Medicine I, University of Cologne, Cologne, Germany
    Leuk Lymphoma 44:15-22. 2003
    ..To assess the prognostic implications of PET in the post-therapeutic setting, we performed a MedLine Search and reviewed the current available studies on this important issue together with our own data...
  9. ncbi request reprint [Artificial sweeteners--are they potentially carcinogenic?]
    M R Weihrauch
    Klinik I fur Innere Medizin, Universitat zu Koln
    Med Klin (Munich) 96:670-5. 2001
    ..It can be assumed that every citizen of the western countries is using artificial sweeteners--knowingly or not. A cancer-inducing activity of one of these substances would mean a health risk to an entire population...
  10. ncbi request reprint Immunomagnetic enrichment and detection of isolated tumor cells in bone marrow of patients with epithelial malignancies
    Martin R Weihrauch
    Department of Internal Medicine I of the University of Cologne, Germany
    Clin Exp Metastasis 19:617-21. 2002
    ..None of the negative controls showed any CK+ cells. Enrichment with magnetically labeled anti cytokeratin antibodies increases the detection rate of epithelial cells in bone marrow of cancer patients compared to immunocytology...
  11. ncbi request reprint Immunomagnetic enrichment and detection of micrometastases in colorectal cancer: correlation with established clinical parameters
    Martin R Weihrauch
    Department of Internal Medicine I, University of Cologne, Germany
    J Clin Oncol 20:4338-43. 2002
    ..We used magnetic activated cell sorting (MACS), a highly sensitive method, to increase detection rates and correlated the presence of cytokeratin (CK)-expressing cells with clinical parameters...
  12. ncbi request reprint Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease
    M R Weihrauch
    Department of Internal Medicine I, University of Cologne, Immunologisches Labor Haus 16, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    Ann Hematol 81:20-5. 2002
    ..However, PET should not be used as the only imaging modality as it failed to detect CT-positive, active tumor regions in some cases...
  13. ncbi request reprint Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
    M R Weihrauch
    Department of Internal Medicine I, University of Cologne, Germany
    Blood 98:2930-4. 2001
    ..On the other hand, a positive PET result indicates a significantly higher risk of relapse and demands further diagnostic procedures and a closer follow-up...
  14. doi request reprint Analysis of Tie2-expressing monocytes (TEM) in patients with colorectal cancer
    Valentin Goede
    Department of Internal Medicine I, University Hospital Cologne, Center of Integrated Oncology Cologne Bonn, Cologne, Germany
    Cancer Invest 30:225-30. 2012
    ..These unexpected findings are at odds with murine tumor models and question the diagnostic or therapeutic value of TEM in human cancer...
  15. ncbi request reprint In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma
    Marc Beyer
    Molecular Tumor Biology and Tumor Immunology, Clinic I for Internal Medicine, University of Cologne, Joseph Stelzmann Strasse 9 Haus 16, 50931 Cologne, Germany
    Blood 107:3940-9. 2006
    ..These findings strongly suggest that the increase of functional T(reg) cells in cancer patients is a response to the process of malignant transformation...
  16. ncbi request reprint Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy
    Eisei Kondo
    1st Department of Internal Medicine, Max Eder Nachwuchsgruppe der Deutschen Krebshilfe, University Hospital of Cologne, Cologne, Germany
    Clin Cancer Res 14:6574-9. 2008
    ..We attempted to induce autologous CTL from healthy donors and patients with cyclin D1-overexpressing tumors using a highly efficient T-cell expansion system based on CD40-activated B cells as antigen-presenting cells...
  17. doi request reprint Toll-like receptor 9 agonists as cancer therapeutics
    Udo Holtick
    University of Cologne, Department I for Internal Medicine, Hematology, Oncology, Cologne, Germany
    Expert Opin Investig Drugs 20:361-72. 2011
    ..Several synthetic TLR9 agonists have been developed for clinical grade use and displayed substantial efficacy in the preclinical and clinical models...
  18. ncbi request reprint Targeting malignant B cells as antigen-presenting cells: TLR-9 agonist induces systemic regression of lymphoma
    Nela Klein-Gonzalez
    Department I for Internal Medicine, Hematology, Oncology, University of Cologne, Germany
    Expert Rev Vaccines 10:295-8. 2011
    ..TLR-9 in situ vaccination combined with local radiotherapy clearly warrants further in-depth analysis and investigation in a Phase III randomized trial, and may provide a new opportunity for the treatment of B-cell malignancies...
  19. ncbi request reprint Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy
    Anke S Krause
    Department for Internal Medicine I, University of Cologne, Cologne, Germany
    Leuk Lymphoma 43:2139-43. 2002
    ..CPDG2 provides an alternative route of MTX elimination by converting it to inactive and non-toxic metabolites. CPDG2 rescue was well tolerated, safe and very effective in preventing severe or life-threatening MTX toxicity...